WBI Investments’s Impax Laboratories, Inc. IPXL Stock Holding History

WBI Investments’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-132,469	Closed	-$3.14M	–	261
2014 Q3	$3.14M	Buy	+132,469	New	+$3.39M	0.09%	116

Other funds holding IPXL

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

WBI Investments's IPXL Position: Q4 2014 in Review

WBI Investments sold out of Impax Laboratories, Inc. (IPXL) in Q4 2014, closing a stake of 132,469 shares — an estimated $3.14M sold.

WBI Investments first reported a position in IPXL in Q3 2014 and held it in 1 quarter. The position peaked at $3.14M in Q3 2014. 178 funds tracked by Wall St. Rank hold IPXL as of Q4 2014.

WBI Investments reported no remaining Impax Laboratories, Inc. position as of Q4 2014 after selling out during the quarter.
WBI Investments sold 132,469 Impax Laboratories, Inc. shares in Q4 2014, an estimated $3.14M.
WBI Investments first reported a position in Impax Laboratories, Inc. in Q3 2014 and held it in 1 quarter.
WBI Investments's Impax Laboratories, Inc. position peaked at $3.14M in Q3 2014.
178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2014.

Based on WBI Investments's 13F filing for Q4 2014, filed 12 Feb 2015.